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Pantothenate kinase-associated neurodegeneration (PKAN) is a familial or sporadic disease characterized by extrapyramidal and
corticospinalsignswithdementia.Patientsshowironaccumulation inthebasalganglia,withneuronallossandgliosis.Amutation
of pantothenate kinase (PANK2) gene localized on chromosome 20p13 has been described in familiar forms, as well as in sporadic
patients. We sought to assess sleep characteristics, including muscle activity during REM sleep, in three patients with PANK2
gene mutation-conﬁrmed diagnosis of PKAN. Sleep architecture was altered in all patients with reduced total time of sleep in
two and lack of SWS in one. No signiﬁcant apnea/hypopnea were detected, and mild PLMS were observed in one patient (PLMS
index:10.7/h). In contrast with other neurodegenerative diseases, no REM sleep abnormalities, especially REM sleep behavior
disorder, were observed in PKAN patients, and percentage of both REM sleep atonia and phasic EMG activity were within normal
ranges. Sleep studies may phenotypically diﬀerentiate PKAN from other neurodegenerative disorders.
1.Introduction
Pantothenate kinase-associated neurodegeneration (PKAN),
previously known as Hallervorden-Spatz disease, is a rare,
progressive, familial or sporadic extrapyramidal dysfunction
withdementiaassociatedwithironaccumulationinthebasal
ganglia. PKAN is an inherited condition recessively linked
to chromosome 20 [1], and mutations in the pantothenate
kinase 2 (PANK2) gene on chromosome 20p13 have been
recently described in this disorder [2, 3].
PKAN patients show excessive iron deposition in the
Globus Pallidus (GP) and Substantia Nigra pars reticulate
(SNr) associated to neuronal loss and gliosis. Generalized
brain atrophy including caudate nuclei, SN, and mesen-
cephalic tegmentum may also occur. Tau-positive neuroﬁb-
rillary tangles and alpha-synuclein-positive Lewy bodies may
be found in cortical and subcortical regions in patients with
prolonged clinical course [4].
PKAN is characterized by progressive extrapyramidal
signs (rigidity, dystonia, and choreoathetosis), corticospinal
signs (spasticity, hyperreﬂexia), and cognitive dysfunctions.
Typical presentation symptoms include extrapyramidal
signs, gait diﬃculty, and intellectual subnormalities, that
mostcommonlyoccurinlatechildhoodorearlyadolescence.
Optic atrophy, retinitis pigmentosa, and seizures are acces-
sory symptoms [3].
Changes in both macro-and microstructure of sleep and
sleep disorders, such as REM sleep behavior disorder (RBD),
Periodic Leg Movements (PLM), Restless Legs Syndrome
(RLS),and ObstructiveSleep Apnea Syndrome (OSAS),have
been associated with most extrapyramidal diseases includ-
ing Parkinson’s disease [5], Multiple System Atrophy [6],
Cortico-Basal Degeneration [7, 8], Progressive Supranuclear
Palsy [9], Lewy body dementia [10], Gilles de la Tourette
syndrome [11], and Huntington’s chorea [12].2 Parkinson’s Disease
Brainstem aminergic systems, including noradrenergic
and serotoninergic projections, as well as mesocorticolimbic
and nigrostriatal dopaminergic pathways, are involved in
the sleep-wake cycle regulation and in behavioral state
modulation, and basal ganglia are thought to be implicated
in the complex mechanism regulating muscle atonia during
REM sleep [13]. To our knowledge, sleep characteristics of
patientswithPKANhavenotbeenreportedsofar.Wesought
to evaluate the sleep features, including the occurrence of
abnormal muscle activity during sleep (REM sleep without
atonia, RBD, and PLMS), in three patients diagnosed as
PKAN based on the presence of a homozygous PANK2 gene
mutation.
2.SubjectsandMethods
Patients 1 and 2 are two previously reported siblings of
Sardinian origin diagnosed with PKAN. Patients 1 is a 25-
year-old woman who developed at age 16 slurred speech,
postural tremor in both hands (7-8Hz), and increasing
gait problems. She then showed dystonic posturing of
both hands, mild action face dystonia and leg rigid-
ity with balance impairment. Later her speech became
dysarthric, a nasal voice appeared and a Babinski sign
was revealed at neurological examination. Patient 2 devel-
oped hypophonia, slurred speech, and action dystonia in
lower extremity at age 20. Later emergence of behavioral
disturbance and impulse dyscontrol required antipsychotic
medication (quetiapine 100mg/day) discontinued after few
months. In both patients, an extended neuropsychological
evaluation revealed a frontosubcortical dysfunction. T2-
weighted MRI showed decreased signal intensity in the
pallidal nuclei with a centrally located area of increased
intensity, giving the “eye-of-the tiger” appearance. Their
SPECT with [123 I]FP-CIT revealed normal dopaminergic
presynaptic function and showed central pallidum and SNr
involvement [14]. These patients were homozygous for a
missense mutation (556 C to T) in PANK2 gene, which
results in an amino acid substitution (arginine to cysteine
at position 176) [15]. The mutation found in these patients
also occurred in one unrelated Italian patient who was
ac o m p o u n dh e t e r o z y g o t e[ 2]. Patient 3 clinical, genetic
and imaging data have been previously published in [16].
He is a 54-year-old man who developed at age of 30
years personality changes associated with choreoathetosis
and postural tremor of the right hand and leg. Because
of behavioral problems he had been initially treated with
neuroleptics (haloperidol and later pimozide) with partial
beneﬁt on psychiatric symptoms but with worsening of
gait and postural instability associated with occasional falls.
He then came to the neurological attention with bilateral
bradykinesia, dystonia of upper and lower right limbs, mild
postural tremor, freezing gait with severe postural instability
and retropulsion, and severe dysarthria. Because of speech
problems,hiscognitioncouldnotbeextensivelyinvestigated,
but recognition and spatial-temporal orientation appeared
normal. He also showed stereotyped movements, hyper-
reﬂexia and orofacial dyskinesias. On MRI T2-weighted
images, pallidal nuclei showed the typical “eye-of-the tiger”
feature. Additionally, SPECT imaging with [123 I]-Ioﬂupane
(DaTSCAN), a dopamine transporter (DAT) tracer, showed
a mild uniform DAT decrement on the right striatum with
normal uptake values in the left striatum. Genetic studies
revealed two heterozygous mutations in the PANK2 gene:
775 G > A and 1141 C > T. The ﬁrst one was a missense
mutation which resulted in an amino acid substitution
(glycine replaced by arginine in position 259). The 1141
C > T was a nonsense mutation that leads to a truncated
protein.
Patients 1 and 2 had no history of insomnia and
their sleep schedule was regular at the time of the study.
Patient 3 complained of occasional diﬃculties of initiating
or maintaining sleep. None of the patients complained of
RLS and there was no history of repetitive limb movements
during sleep, violent motor behaviors associated to dream
mentation or other parasomnia. Patients 1 and 2 were
not taking psychotropic drugs at the time of the study,
while patient 3 was taking levodopa (150mg/day) and
clonazepam (2mg at noon and at bedtime) since at least
two years, the latter because of the presence of myoclonic
jerks.
The study was approved by the local ethics committees
and patients gave written informed consent. All patients
underwent one night of Video-Polysomnographic (VPSG)
recording in the sleep laboratory, after one adaptation night.
Sleep was recorded and scored according to Rechtschaﬀen
and Kales’ method, using 30-second epochs. PSG included
electroencephalographic recording (C3/A2, C4/A1, accord-
ing to the 10–20 international electrode placement system),
right and left electrooculogram, and chin electromyogram.
Recording of oral and nasal air ﬂow, thoracic and abdominal
movements, and oximetry was performed to detect apneas
or hypopneas. Surface EMG of the right and left anterior
tibialis muscles was recorded to quantify leg movements. An
additional surface EMG of right deltoid muscle was recorded
to quantify upper limb movements.
Electrocardiogram was recorded from a standard D2
lead. Periodic leg movements during sleep (PLMS) was
recorded and scored according to standard criteria, that is,
legmovementslasting0,5to5seconds,separatedbyintervals
of 4 to 90 seconds and occurring in series of at least four
consecutive movements. Microarousals were scored an the
C3-A2EEGleadusingtheASDAcriteria.Microarousalindex
(number per hour of sleep) was calculated, as well as the
percentage of PLMS associated with microarousals (PLMS-
MA). A PLMS was considered associated with microarousal
when the latter started within 2 seconds before or after
the onset of PLMS. Percentages of REM sleep atonia
and of phasic chin EMG activity during REM sleep were
measured, according to the method described by Lapierre
and Montplaisir [17]. Furthermore, to better assess motor
activity during REM sleep, phasic EMG activity of the upper
andlowerlimbswasalsorecordedintheright deltoidmuscle
and in both tibialis muscles. Lower limb phasic activity was
obtained by averaging the values of the activity recorded in
both tibialis muscles.Parkinson’s Disease 3
3. Results
PSGcharacteristicsareshowninTable 1.Totalsleeptimewas
reduced in both patients 1 and 2, with low sleep eﬃciency
due to prolonged periods of wakefulness after sleep onset.
The same variables were normal in patient 3. Percentage
of SWS was normal to elevated in patients 1 and 2, while
SWS was virtually missing in patient 3. Sleep spindle and
K complex were normally represented in all patients, and
microarousal index was within the normal range. None of
the three patients was found to have apnea (AHI < 5) and
oxyemoglobin saturation was always higher than 90% in
all patients through the night. PLMS were not observed in
patients 1 and 2. Patient 3 showed mild PLMS (PLMS index:
10.5/h) almost exclusively during NREM sleep, and rarely
associated to microarousals. Beside PLMS, no other motor
behaviors were observed during sleep in these patients. Tonic
and phasic features of REM sleep are shown in Table 2.T h e
totality of epochs of REM sleep were classiﬁed as atonic
(mean % of REM sleep atonia: 100%) in all patients. There
was a very low percentage of phasic EMG activity during
REM sleep in either chin, upper and lower limbs muscles
in all patient, with the mean values of 0.47, 0.43 and 2.70,
respectively. Furthermore, no abnormal phasic EMG activity
was observed during NREM sleep.
4. Discussion
Sleep architecture was altered in all PKAN patients. Indeed,
the two unmedicated sibling patients showed a severe
reduction of total time of sleep, with a normal and even
increased percentage of SWS. The third patient showed
a normal amount of sleep, with increased percentage of
light sleep and no SWS. The latter ﬁnding may be partly
ascribed to pharmacological eﬀects, since benzodiazepines
are known to reduce SWS, although these eﬀects tend to
decrease with chronic intake at stable doses, as was the case
of patient 3. Alternatively, the lack of SWS in this patient
could be related to older age, longer disease duration and
severity of neurodegeneration. Indeed, diﬀerences in sleep
pattern might reﬂect the clinical heterogeneity of the disease,
since early and late onset PKAN diﬀer in terms of clinical
presentation. Despite alterations in macrostructure, no frag-
mentation of sleep microstructure, for example, increased
number of microarousal, was observed. Nevertheless, in all
patients no other sleep disorders were detected, particularly
there were no signiﬁcant apnea or hypopnea, and very mild
PLMS were observed only in the oldest patient. Moreover,
none of the subjects showed clinical episodes of REM
sleep behavior disorder. Of interest, in contrast with other
neurodegenerative diseases (particularly with most alpha-
synucleinopathies), REM sleep atonia was found to be totally
preserved, with a percentage of REM sleep atonic epochs
of 100% in all patients. Phasic EMG activity during both
REM and NREM sleep was also normal, and perhaps even
decreased in these patients, when compared to published
normal values [18]. REM sleep muscle atonia area, located
mainly in the brainstem, are strictly interconnected with
basalganglia.Peduncolo-pontinenucleus(PPN),involved in
Table 1: Polysomnographic characteristics of patients with PKAN.
Patient 1 Patient 2 Patient 3
Age 25 30 54
Gender FMM
Age of onset of
PKAN
16 20 30
Sleep latency
(min.)
2.5 41 13
Total sleep time
(min.)
250 280.5 384.9
N. of
awakenings
91 03
Wake after sleep
onset (WASO)
177 141 10.5
Sleep eﬃciency
(%)
58.6 60.6 94.2
%S t a g e1s l e e p 3.1 8.2 1.2
%S t a g e2s l e e p 53.3 55.4 77.2
%S W S 26.4 27.7 0.3
%S t a g eR E M
sleep
17.2 8.7 21.4
N. of REM
periods
422
MA index 4.6 7.3 10.1
PLMS index 0 0 10.9
% PLMS
associated with
MA
— — 21.6
AHI 00 1 . 5
SWS: Slow Wave Sleep; REM: Rapid Eye Movements; MA: Microarousals;
PLMS: Periodic Leg Movements during sleep; PLMW: Periodic Leg Move-
ments during wakefulness; AHI: Apnea-Hypopnea Index.
Table 2: Polysomnographic features of REM sleep in PKAN.
Patient 1 Patient 2 Patient 3
% REM sleep atonia 100 100 100
% phasic EMG activity
chin 0.3 0 1.4
deltoids 0 0.1 1.2
tibialis 0.6 2.7 4.8
the muscle tone inhibitory control during both wakefulness
and sleep, receives inhibitory GABAergic projections from
SNr and from the internal part of GP (GPi). Although no
pathological data about these patients are available, it may be
hypothesized that neuronal loss and iron inclusions usually
observed in Gpi and in SNr in patients with PKAN would
result in reduced inhibitory outputs to PPN with normal or
even enhanced muscle atonia during REM sleep.
This is the ﬁrst description of sleep characteristics and
REM sleep features in patients with PKAN. If replicated in a
largerseriesofPKANpatients,theﬁndingofanormalmotor
control during sleep might help in diﬀerentiating PKAN
from other neurodegenerative conditions and may shed light
on the role of basal ganglia in modulating REM sleep atonia.4 Parkinson’s Disease
References
[1] T.D.Taylor,M.Litt,P.Kramer,etal.,“Homozygositymapping
of Hallervorden-Spatz syndrome to chromosome 20p12.3-
p13,” Nature Genetics, vol. 14, no. 4, pp. 479–481, 1996.
[2] B. Zhou, S. K. Westaway, B. Levinson, M. A. Johnson, J.
Gitschier, and S. J. Hayﬂick, “A novel pantothenate kinase
gene (PANK2) is defective in Hallervorden-Spatz syndrome,”
Nature Genetics, vol. 28, no. 4, pp. 345–349, 2001.
[ 3 ]M .T .P e l l e c c h i a ,E .M .V a l e n t e ,L .C i f ,e ta l . ,“ T h ed i v e r s e
phenotype and genotype of pantothenate kinase-associated
neurodegeneration,”Neurology,vol.64,no.10,pp.1810–1812,
2005.
[4] M. Neumann, S. Adler, O. Schluter, E. Kremmer, R. Benecke,
and H. A. Kretzschmar, “Alpha synuclein accumulation in
a case of neurodegeneration with brain iron accumulation
type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with
widespread cortical and brainstem-type Lewy bodies,” Acta
Neuropathologica, vol. 100, no. 5, pp. 568–574, 2000.
[5] C. L. Comella, “Sleep disturbances in Parkinson’s disease,”
Current Neurology and Neuroscience Reports, vol. 3, no. 2, pp.
173–180, 2003.
[6] G. Plazzi, R. Corsini, F. Provini, et al., “REM sleep behavior
disorders in multiple system atrophy,” Neurology, vol. 48, no.
4, pp. 1094–1097, 1997.
[7] T. C. Wetter, H. Brunner, V. Collado-Seidel, C. Trenkwalder,
and J. Winkelmann, “Sleep and periodic limb movements in
corticobasal degeneration,” Sleep Medicine,v o l .3 ,n o .1 ,p p .
33–36, 2002.
[ 8 ]E .M .G a t t o ,M .C .U r i b eR o c a ,O .M a r t ´ ınez, S. Valiensi,
and B. H¨ ogl, “Rapid eye movement (REM) sleep without
atonia in two patients with corticobasal degeneration (CBD),”
ParkinsonismandRelatedDisorders,vol.13,no.2,pp.130–132,
2007.
[9] I. Arnulf, M. Merino-Andreu, F. Bloch, et al., “REM sleep
behavior disorder and REM sleep without atonia in patients
with progressive supranuclear palsy,” Sleep,v o l .2 8 ,n o .3 ,p p .
349–354, 2005.
[10] B. F. Boeve, M. H. Silber, T. J. Ferman, J. A. Lucas, and
J. E. Parisi, “Association of REM sleep behavior disorder
and neurodegenerative disease may reﬂect an underlying
synucleinopathy,” Movement Disorders, vol. 16, no. 4, pp. 622–
630, 2001.
[11] S. Cohrs, T. Rasch, S. Altmeyer, et al., “Decreased sleep
qualityandincreasedsleeprelatedmovementsinpatientswith
Tourette’s syndrome,” Journal of Neurology Neurosurgery and
Psychiatry, vol. 70, no. 2, pp. 192–197, 2001.
[12] I. Arnulf, J. Nielsen, E. Lohmann, et al., “Rapid eye movement
sleep disturbances in Huntington disease,” Archives of Neurol-
ogy, vol. 65, no. 4, pp. 482–488, 2008.
[13] D. B. Rye, “Contributions of the pedunculopontine region to
normal and altered REM sleep,” Sleep, vol. 20, no. 9, pp. 757–
788, 1997.
[14] G. Cossu, C. Cella, M. Melis, et al., “[123I]FP-CIT SPECT
ﬁndings in two patients with Hallervorden-Spatz disease with
homozygousmutationinPANK2gene,”Neurology,vol.64,no.
1, pp. 167–168, 2005.
[15] G. Cossu, M. Melis, G. Floris, S. J. Hayﬂick, and A.
Spissu, “Hallervorden-Spatz syndrome (pantothenate kinase
associated neurodegeneration) in two sardinian brother with
homozygous mutation in PANK2 gene,” Journal of Neurology,
vol. 249, no. 11, pp. 1599–1600, 2002.
[16] A. Antonini, S. Goldwurm, R. Benti, et al., “Genetic, clinical,
and imaging characterization of one patient with late-onset,
slowly progressive, pantothenate kinase-associated neurode-
generation,” Movement Disorders, vol. 21, no. 3, pp. 417–418,
2006.
[17] O. Lapierre and J. Montplaisir, “Polysomnographic features
of REM sleep behavior disorder: development of a scoring
method,” Neurology, vol. 42, no. 7, pp. 1371–1374, 1992.
[18] Y. Dauvilliers, S. Rompr´ e, J.-F. Gagnon, M. Vendette, D. Petit,
and J. Montplaisir, “REM sleep characteristics in narcolepsy
and REM sleep behavior disorder,” Sleep,v o l .3 0 ,n o .7 ,p p .
844–849, 2007.